Q-omics provides the consensus-scored CBS profile across patient tissues and cancer cell-line models. CBS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CBS is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CBS RNA expression shows 17,033 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CBS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBS survival associations across molecular data types. CBS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBS RNA expression–survival associations across cancer types. High CBS expression shows unfavorable associations in KIRC, MESO, ACC, UVM and UCEC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CBS RNA expression.
This table summarizes CBS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CBS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBS shows lower tumor expression in KIRC and CHOL and higher tumor expression in HNSC, BLCA, LUAD and BRCA. The KIRC box plot shows higher CBS RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p < 0.001).
This table shows molecular features associated with CBS in patient tissues and cancer cell lines. In patient samples, CBS shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
